About: Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis
Creator	Almas, Talal Fischman, David Roomi, Sohaib Saeed, Rehan Sattar, Yasar Ullah, Waqas Abdullah, Hafez Ahmad, Ammar Chadi Alraies, M Haas, Donald Mukhtar, Maryam Narayana Gowda, Smitha Oliver, Tony
Source	Medline; PMC
abstract	BACKGROUND: During the initial phases of the coronavirus disease 2019 (COVID-19) epidemic, there was an unfounded fervor surrounding the use of hydroxychloroquine (HCQ); however, recently, the Centers for Disease Control and Prevention (CDC) has recommended against routine use of HCQ outside of study protocols citing possible adverse outcomes. METHODS: Multiple databases were searched to identify articles on COVID-19. An unadjusted odds ratio (OR) was used to calculate the safety and efficacy of HCQ on a random effect model. RESULTS: Twelve studies comprising 3,912 patients (HCQ 2,512 and control 1400) were included. The odds of all-cause mortality (OR: 2.23, 95% confidence interval (CI): 1.58 - 3.13, P value < 0.00001) were significantly higher in patients on HCQ compared to patients on control agent. The response to therapy assessed by negative repeat polymerase chain reaction (PCR) (OR: 1.83, 95% CI: 0.50 - 6.75, P = 0.36), radiological resolution (OR: 1.98, 95% CI: 0.47 - 8.36, P value = 0.36) and the need for invasive mechanical ventilation (IMV) (OR: 1.21, 95% CI: 0.34 - 4.33, P value = 0.76) were identical between the two groups. Overall, four times higher odds of net adverse events (NAEs) were observed in the HCQ group (OR: 4.59, 95% CI 1.73 - 12.20, P value = 0.02). The measures for individual safety endpoints were also numerically lower in the control arm; however, none of these values reached the level of statistical significance. CONCLUSIONS: HCQ might offer no benefits in terms of decreasing the viral load and radiological improvement in patients with COVID-19. HCQ appears to be associated with higher odds of all-cause mortality and NAEs.
has issue date	2020-07-04(xsd:dateTime)
bibo:doi	10.14740/jocmr4233
bibo:pmid	32849936
has license	cc-by-nc
sha1sum (hex)	f5ad20f303a02a8e047e18bcef0af657054f2f6e
schema:url	https://doi.org/10.14740/jocmr4233
resource representing a document's title	Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis
has PubMed Central identifier	PMC7430873
has PubMed identifier	32849936
schema:publication	J Clin Med Res
resource representing a document's body	covid:f5ad20f303a02a8e047e18bcef0af657054f2f6e#body_text
is schema:about of	named entity 'META-ANALYSIS' covid:arg/f5ad20f303a02a8e047e18bcef0af657054f2f6e named entity 'Safety' named entity 'Hydroxychloroquine' named entity 'COVID' named entity 'epidemic' named entity 'study protocols' named entity 'COVID' named entity 'selection bias' named entity 'HCQ' named entity 'respiratory complications' named entity 'COVID' named entity 'HCQ' named entity 'standard of care' named entity 'Middle Eastern respiratory syndrome' named entity 'MeSH' named entity 'chronic kidney disease' named entity 'MeSH' named entity 'HCQ' named entity 'Cochrane' named entity 'Subgroup analysis' named entity 'EndNote' named entity 'azithromycin' named entity 'NAE' named entity 'HCQ' named entity 'PCR' named entity 'control arm' named entity 'PCR' named entity 'zinc' named entity 'lymphopenia' named entity 'meta-analysis' named entity 'immunopathology' named entity 'HCQ' named entity 'viruses' named entity 'control arm' named entity 'HCQ' named entity 'HCQ' named entity 'Meta-Analyses' named entity 'odds ratio' named entity 'statistical model' named entity 'control groups' named entity 'COVID' named entity 'HCQ' named entity 'coronavirus disease 2019' named entity 'control group' named entity 'Food and Drug Administration' named entity 'statistical analysis' named entity 'HCQ' named entity 'HCQ' named entity 'HCQ' named entity 'MeSH' named entity 'Systematic Reviews' named entity 'cardiomyopathy' named entity 'patient outcomes' named entity '95% confidence interval' named entity 'QT prolongation' named entity 'follow-up' named entity 'control group' named entity 'detection bias' named entity 'HCQ' named entity 'zinc' named entity 'azithromycin' named entity 'antiviral' named entity 'significant difference' named entity 'artificial ventilation' named entity 'HCQ' named entity 'gastrointestinal' named entity 'virus' named entity 'HCQ'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software